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Mycoplasmas and Human prostate cancer:  An exciting but 
cautionary note
Shyh-Ching Lo, Shien Tsai
A recent study of Barykova, et al. [1] described a 
significant  association  between  Mycoplasma hominis 
infection and development of prostate cancer. In the study, 
the authors detected the presence of M. hominis-specific 
DNA sequences in examining 496 prostate biopsies by 
PCR obtained from 248 Russian men undergoing cancer 
diagnosis. The association appeared to be particularly 
significant in the statistical analysis between M. hominis 
infection and development of the higher grade prostate 
cancer. A possible role for mycoplasmas in association 
with  human  malignancy  was  first  noted  during  1960s. 
Several studies reported isolation of mycoplasmas from 
human leukemic bone marrow [2-6]. A majority of the 
mycoplasmas isolated in the studies were identified as 
Mycoplasma fermentans.  However,  the  mycoplasma-
oncogenesis hypothesis failed to advance because the 
same mycoplasmas later could also be found in non-
leukemic children or adults, although the mycoplasmas 
appeared to be most frequently isolated from patients with 
leukemia [7]. Koch’s postulate of identifying the causative 
agent  in  an  infectious  disease  by  finding  a  specific 
pathogen uniquely present in a particular disease process 
overshadowed the characteristics in both chronicity and 
multi-factorial nature of the malignant process. 
Mycoplasmas are a heterogeneous group of very 
small  organisms  capable  of  self-replication.  The  wall-
free  microbes  can  cause  a  wide  variety  of  diseases 
in animals. Some mycoplasmas cause respiratory or 
urogenital  diseases  in  humans.  However,  many  other 
mycoplasmas chronically colonize our respiratory and 
urogenital  tracts  without  apparent  clinical  significance 
[8]. Various mechanisms including “antigenic variation” 
may be critical in the ability of these microbial species 
to evade host antibody responses or other elements of 
immune  recognition  [9].  Most  interestingly,  the  wall-
free mycoplasmas are among the few prokaryotes that 
can  grow  essentially  “symbiotically”  in  cultures  of 
mammalian host cells. Mycoplasmas are often growing in 
a close interaction with mammalian cells for a very long 
period of time without producing detectable cytopathic 
effects on the infected host cells. Thus, their infections 
in cell cultures are commonly unrecognized. However, 
we believe the interplay between human hosts and these 
unusual microbes is complex and can be important in 
the development of various human chronic illnesses 
including cancers. Our laboratory at the Armed Forces 
Institute of Pathology (AFIP) had long been interested in 
unusual infections of mycoplasmas. We have previously 
hypothesized chronic infections by the seemingly 
low  virulent  microbes  could  produce  a  previously 
unrecognized form of pathogenesis such as neoplasia in 
the infected mammalian hosts [10]. 
Over  the  years,  we  developed  several  in vitro 
mycoplasma-oncogenesis models to demonstrate that 
infections of mycoplasmas could not only damage 
DNA or genes of infected mammalian cells but also 
disturb the cell cycle check points that control normal 
cell division and the process of apoptosis by providing 
potent altered cell growth signals [11]. Various signals 
could continually be sent through close interacting with 
mycoplasmas from the surface of chronically infected 
host cells to alter the expression of many different genes, 
thus significantly affect crucial biological characteristics 
including  control  of  cell  growth  [10,  11].  Thus,  we 
hypothesized that chronic infections by mycoplasmas 
produced genetic instability and chromosomal aberrations 
in the mycoplasma-infected cells that however failed to 
undergo proper apoptosis due to mycoplasma-mediated 
mitogenic  and  anti-apoptotic  effects  would  gradually 
lead to the consequence of malignant transformation 
[10-12].  Studies of in vitro  model  systems,  which  are 
confined to a fixed condition and may not describe the 
full range of activities occurring in the infected host, 
could nevertheless provide valuable information on 
mechanisms of malignant cell transformation. We believe 
the chronic persistent infection models of mycoplasmas 
developed have provided an excellent in vitro model 
system for cancer research. Most importantly, the in vitro 
mycoplasma-oncogenesis models developed have a long 
latency  with  a  multi-stage  malignant  progression,  one 
of the most common paradigms in naturally occurring 
human cancers [13]. 
Mycoplasmas are ubiquitously colonizing in both 
respiratory and urogenital tracts of human body. The 
most frequently identified Mycoplasma species in human 
urogenital tract are M. hominis, Ureaplasma urealyticum 
and M. genitalium.  Naturally,  one  would  suspect  that 
some of these urogenital mycoplasmas could also infect 
or colonize prostate and play an important role in the 
prostate disease processes like hyperplasia or cancer. In 
the present publication of Barykova, et al. [1], the results 
showed a statistically significant association between M. 
hominis infection and development of prostate cancer. Oncotarget 2011; 2:  352 - 355 353 www.impactjournals.com/oncotarget
This study in Russian men is the first report demonstrating 
the clinical association between M. hominis infection in 
prostate  and  prostate  cancer  formation. The  significant 
association could be found in PCR assay of detecting 
M. hominis-specific DNA, 16S r-RNA and IgG serology 
studies. The presence of M. hominis in some of the prostate 
biopsies (6.3%), although at a lower frequency, could be 
confirmed  by  isolation  of  the  mycoplasma  by culture. 
However, the culture isolation and characterization of M. 
hominis from prostate biopsies with or without pathology 
should be further studied with great care in the future to 
confirm the association. In a similar note, since many men 
may have M. hominis colonization in the urogenital tract 
as commensal, the background of anti-M. hominis IgG 
level was found to be high and significantly varying with 
men’s age. Interestingly, we previously reported men older 
than 60 showed marked decrease of M. hominis infection 
by serology [14)]. Large-scale epidemiological studies as 
proposed to be conducted by authors of the article will 
indeed be required to demonstrate the association between 
M. hominis infection and prostate cancer contracted 
mainly by older males. Other urogenital mycoplasmas 
such as M. genitalium should also be further examined for 
their potential involvement in the prostate disease process. 
Parallel studies of other human uogenital mycoplasmas 
could certainly serve as an important control for M. 
hominis.
In addition to large-scale epidemiological studies 
proposed by Barykova et al. to confirm the significance 
of their observations, it also would be essential to develop 
an in vitro cell culture model as well as an animal model 
for further evaluation of the role of M. hominis in the 
development and progression of prostate carcinogenesis. 
In this context, Namiki et al. [15] recently reported that 
chronic exposure of the immortalized human benign 
prostate cell line, BPH-1 to M. hyorhinis or M. genitalium 
could induce malignant transformation of the prostate 
epithelial cells. The prolonged mycoplasma-infected BPH-
1 cells evidently gained the critical malignant property 
of forming tumor when introduced into nude mice. We 
expect that chronic infection with M. hominis would also 
induce BPH-1 cells to undergo malignant transformation, 
as demonstrated by the infections of M. hyorhinis and M. 
genitalium. However, it may be important to note that 
the immortalized human BPH-1 cell line was previously 
established by transduction of SV40 T-antigen into primary 
cultures of prostatic epithelial cells. The BPH-1 cells 
expressing the viral antigen might be more susceptible to 
malignant transformation when exposed to the appropriate 
stimulation such as mycoplasma infections. Therefore, the 
role of mycoplasma infection played in the BPH-1 cell 
culture model could be related to the promotion of host 
cell to undergo further progression to a more malignant 
phenotype, rather than an initiation of cell transformation 
(15). Using human PBMCs in the cultures that normally 
died quickly in the first few weeks, our previous study 
showed  introduction  of  M. fermentans (Mi  and  PG18 
strains) into the PBMC cultures would markedly enhance 
the blood cells to undergo immortalization [16]. Since all 
the immortalized lymphocytes obtained after many months 
were  found  to  be  positive  for  EBV  latent  membrane 
protein (LMP1) antigen, the mycoplasma-mediated effect 
in blood cell immortalization could also be promotional 
effect, instead of initiation effect. 
It has long been documented in both clinical and 
pathological studies that majority of men older than 50 
years have various form/degree of hyperplasia and a 
very significant proportion (~50%) among them already 
harbor prostate cancer. However, only a small percent of 
the prostate cancer will continue to progress into highly 
malignant form and undergo aggressive metastasis. 
Factor(s)  that  could  be  having  significant  promotional 
effect  in  the  patients  with  the  progressive  malignant 
disease  have  never  been  identified.  In  this  context, 
although mycoplasma-mediated initiation effect in 
malignant transformation of mammalian cells has not been 
well  demonstrated,  mycoplasma-mediated  promotional 
effect in immortalization and malignant transformation of 
mammalian cells could be clearly demonstrated in the in 
vitro models as described above. Chronic and persistent 
infections with the unusual prokaryotic microbes known 
to possess potent promotional effect of malignant 
transformation in vitro could similarly play an important 
promotional role in the malignant progression of many 
prostate cancers. Thus, the present finding, if confirmed, 
would have a highly significant impact and lead to the 
development of new approaches of preventions, diagnostic 
tests and therapeutic treatments against prostate cancers. 
Infections Tumor-like Lesions Citations
Mycoplasmal pericarditis Left ventricular hemangioma Boden WE et al. [20]
M. pneumoniae infection
Pleural pseudotumor 
mesothelial cell proliferation
Abo W et al. [21]
M. pneumoniae infection Pseudotumor of the lung Park SH et al. [22]
Table 1: Mycoplasmal infections and development of tumor-like lesions, clinical case reportsOncotarget 2011; 2:  352 - 355 354 www.impactjournals.com/oncotarget
The concept that bacterial infection could lead 
to  cancer  development  in  human  was  first  proposed 
in the late nineteenth and early twentieth century. The 
convincing evidence that linked bacterial infection 
with  the  development  of  various  cancers  was  not 
demonstrated until the association between Helicobacter 
pylori infection and developments of gastric cancer and 
mucosa-associated lymphoid tissue (MALT) lymphoma 
were reported near a hundred years later [17]. Reported 
evidence of infections by other bacteria species associated 
with  cancer  formations  in  human  included  Salmonella 
typhi in gallbladder cancer, Streptococcus bovis in colon 
cancer, and Chlamydia pneumoniae in lung cancer [18, 19]. 
Although the present study may be the first demonstration 
of  an  association  between  mycoplasmal  infections  and 
cancer development, there were several reports of tumor 
growth or development of tumor-like lesions in patients 
with various mycoplasmal infections in lung, pleural sac 
or pericardium in the past (Table 1). Interestingly, these 
pseudo-tumors regressed completely following effective 
antibiotics treatments to eradicate the mycoplasmas. The 
potent mitogenic effects as well as the potent induction 
of  pro-inflammatory  cytokines  of  the  mammalian  cells 
found in the in vitro studies could apparently have equally 
important in vivo effects in the infected patients. It is not 
clear if chronic or prolonged mycoplasmal infections 
could indeed cause genetic alterations and gene instability 
of these rapidly proliferating cells in these tumor-like 
lesions, as clearly documented in many in vitro studies of 
ours and others. Our in vitro model systems have clearly 
demonstrated once these irreversible genetic events occur 
the malignant transformation of these cells would become 
permanent, eradication of mycoplasmas can no longer 
reverse  the  continuous/unrestrained  growth  property  of 
these cells, hence formation of true malignant cancer in 
the infected patients.
In  reviewing  the  exciting  study  finding,  it  is  still 
prudent to note that the high likelihood of both PCR assay 
and mycoplasma isolation as a result of contamination 
from various laboratory procedures could often 
complicate the assessment. This has also been rightly 
pointed out in another commentary on the current report 
published  in  this  issue  of  journal  [23]. The  study  will 
need  to  be  independently  confirmed  under  a  stringent 
condition. As mentioned earlier, further studies, including 
solid epidemiological studies and development of animal 
models, are clearly needed for better assessment of the 
possible role that, if any, mycoplasmas may be playing 
in development or progression of prostate cancer. In 
conclusion, a role for mycoplasmas in any human or 
animal cancers is still conjectural; however the current 
report of demonstrating a significant association between 
M. hominis infection and development of prostate cancer 
has provided an important piece of clinical evidence 
to support the possibility that chronic infection by the 
unusual  wall-free  bacteria  could  lead  to  human  cancer 
development. This report should intrigue many more 
scientists to examine mycoplasma-oncogenesis process 
and to further investigate potential infectious root in 
prostate cancer formation or progression.
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